Neoadjuvant sintilimab in combination with concurrent chemoradiotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: a single-arm phase 2 trial

Neoadjuvant sintilimab in combination with concurrent chemoradiotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: a single-arm phase 2 trial

Abstract In this multicenter, single-arm phase 2 trial (ChiCTR1900024428), patients with locally advanced gastric/gastroesophageal junction cancers receive one cycle of sintilimab (anti-PD1) and chemotherapy (S-1 and nab-paclitaxel), followed by 5 weeks of concurrent chemoradiotherapy and sintilimab...

Full description

Bibliographic Details
Main Authors: Jia Wei, Xiaofeng Lu, Qin Liu, Yao Fu, Song Liu, Yang Zhao, Jiawei Zhou, Hui Chen, Meng Wang, Lin Li, Ju Yang, Fangcen Liu, Liming Zheng, Haitao Yin, Yang Yang, Chong Zhou, Ping Zeng, Xiaoyu Zhou, Naiqing Ding, Shiqing Chen, Xiaochen Zhao, Jing Yan, Xiangshan Fan, Wenxian Guan, Baorui Liu
Format: Article
Language:English
Published: Nature Portfolio 2023-08-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-023-40480-x

Internet

https://doi.org/10.1038/s41467-023-40480-x

Similar Items